Testing effectiveness (Phase 2)Study completedNCT01363297What this trial is testingStudy Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaWho this might be right forAcute Lymphocytic Leukemia Pfizer 72
Testing effectiveness (Phase 2)Ended earlyNCT03698552What this trial is testingADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaWho this might be right forBlasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT04788472What this trial is testingSequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLWho this might be right forB-Cell Acute Lymphoblastic Leukemia, Adult Zhejiang University 28
Large-scale testing (Phase 3)Ended earlyNCT01232556What this trial is testingInotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyWho this might be right forLymphoma, Non-Hodgkin Pfizer 338
Testing effectiveness (Phase 2)WithdrawnNCT03851081What this trial is testingInotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWho this might be right forAllogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT03094611What this trial is testingInotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaWho this might be right forCD22 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center 4
Early research (Phase 1)UnknownNCT03999697What this trial is testingA Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesWho this might be right forDiffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre Lymphoma+4 more PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)UnknownNCT04204161What this trial is testingA Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and LymphomaWho this might be right forRelapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT02981628What this trial is testingInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaWho this might be right forRecurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more Children's Oncology Group 80
Early research (Phase 1)Looking for participantsNCT06752785What this trial is testingCD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.Who this might be right forAcute Lymphoblastic Leukemia Guangzhou Women and Children's Medical Center 10
Testing effectiveness (Phase 2)Ended earlyNCT03913559What this trial is testingInotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaWho this might be right forAcute Lymphoblastic Leukemia St. Jude Children's Research Hospital 5
Large-scale testing (Phase 3)Study completedNCT01564784What this trial is testingInotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaWho this might be right forAcute Lymphoblastic Leukemia Pfizer 326
Testing effectiveness (Phase 2)Study completedNCT02311998What this trial is testingPhase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLWho this might be right forB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+4 more M.D. Anderson Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01562990What this trial is testingPhase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseWho this might be right forDiffuse Large B-Cell Lymphoma The Lymphoma Academic Research Organisation 11
Early research (Phase 1)UnknownNCT04303520What this trial is testingAnti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALLWho this might be right forCD19-positive ALL The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Active Not RecruitingNCT03241940What this trial is testingStudy of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell MalignanciesWho this might be right forB Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+4 more Stanford University 33
Early research (Phase 1)UnknownNCT05523661What this trial is testingDasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL PatientsWho this might be right forPh Positive ALLCAR-T CellDasatinib Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15
Testing effectiveness (Phase 2)Study completedNCT01664910What this trial is testingCMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesWho this might be right forHematopoietic and Lymphoid Cell Neoplasm M.D. Anderson Cancer Center 27
Early research (Phase 1)Study completedNCT02581878What this trial is testingSafety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's LymphomaWho this might be right forLymphoma, Non-Hodgkin Bayer 21
Early research (Phase 1)UnknownNCT02721407What this trial is testingAnti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsWho this might be right forRecurrent Adult Diffuse Large Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell Lymphoma+3 more Xinqiao Hospital of Chongqing 20